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Kiel, Germany
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Results
In Germany a total of 702 allotransplantations of bone marrow (BMT, n = 619) and peripheral blood stem cells Search strategy (PBSCT, n = 83), respectively, have been performed by 34 transplantation teams in 1995. Since these teams operate Definition of the different search types: For allogeneic more or less independently from each other, the strategies BMT and PBSCT there are three different types of donor of donor search, the use of the tissue typing techniques, search, namely CFDS, EFDS and UMDS. Core family and the policy on acceptable HLA mismatches often differ donor search (CFDS) is the search amongst the patient's considerably from one transplant centre to another. This siblings, while extended family donor search (EFDS) refers situation is not only unsatisfactory from a scientific point to the search amongst all other relatives. In contrast, unreof view, since transplantation biology is considered to be lated marrow donor search (UMDS) is the search amongst the same all over Germany, but also confusing for patients HLA-typed volunteers provided by national or foreign who present at more than one centre in order to be grafted. October 1996). The main intention of this change of policy A, HLA-B and low resolution molecular genetic HLA-DRB1 typing of the recipient and his/her prospective is to offer an extra chance to those patients who otherwise have no HLA-matched donor. However we cannot exclude, donor(s) is compulsory and donor selection has to be based on the typing results for these six HLA loci (2 A, 2 B, 2 that advanced donor age might constitute a risk factor for BMT outcome. Thus, until informed otherwise by larger DRB1). Additional HLA-C, HLA-DQB1 and HLA-DPB1 typing is only optional, since the impact of donor/recipient clinical studies, we recommend young donor age to be regarded as a positive selection criterion if more than one mismatches for these HLA loci on transplantation outcome is not (yet) established. If performed, HLA-C, HLA-DQB1 HLA-matched unrelated donor is available.
and/or HLA-DPB1 mismatches do not exclude a relative Sequential use of CFDS, EFDS and UMDS: The unanifrom donating marrow or peripheral blood stem cells. mous view of the participants was that CFDS has to be run Nevertheless, a donor matched with the recipient for all the first if siblings are available. Whenever possible the above HLA loci is considered to be the 'best donor'. patient's parents should be HLA-typed simultaneously with the siblings in order to identify the segregating HLA haploAcceptable HLA mismatches: If a genotypic or phenotypic types of the patient. Furthermore, there was consensus on HLA-identical (ie a fully HLA-matched) relative is not the following aspects of search strategy: In all patients lackavailable, a partially HLA-matched related donor may be ing a core family donor EFDS at least of a limited scope acceptable. 5, 6 By definition this type of donor is genoshould be carried out if feasible.
1 EFDS among the patient's typically HLA haploidentical with the recipient and differs children, cousins, aunts and uncles was reported to be sucfrom the recipient in at least one HLA antigen of the 'noncessful in 11% of the patients lacking a sibling donor.
2 In shared' HLA haplotype. The compromise reached on order to guarantee time-and cost-effectiveness of EFDS acceptable HLA mismatches in the related setting is sumthe search co-ordinator should (1) request the patient's fammarised in Table 1 . For clarity, we would like to comment ily tree by fax or electronic mail; (2) focus on relatives who briefly on the first section of Table 1 : 'Underlying maligare easy to trace and are not hesitant about donation of nant disease'. Since the conditioning regimen is aggressive marrow; (3) preferentially select relatives on the side of the in patients with malignancies, HLA mismatches in the HvG family tree (maternal or paternal) where the less frequent direction are considered to be of limited clinical relevance.
7 of the patient's two HLA haplotypes segregates. On this If a recipient is homozygous for one or more HLA loci side of the family the 'rare' HLA haplotype may have been he/she may exhibit only one HLA mismatch in the GvH directly inherited by several relatives while the chance is direction but two or even three mismatches in the HvG high, that the 'more common' haplotype is also present, direction. Our consensus is that these additional HLA misbeing introduced into the extended family by chance (ie matches in the HvG direction should not exclude a donor marriage); and (4) request blood samples for serological if no better HLA-matched relative is available for an HLA HLA class I and DNA-based HLA class II typing simultaneously by fax or electronic mail. Hence, class II typing can be performed without delay in those relatives who are ence was as follows: In the related setting serological HLA- Table 3 HLA-DRB1 and HLA-DQB1 alleles to be identified for homozygous recipient. There was some debate whether to UMDS (July, 1996) prefer a three locus mismatched related to an HLA-identical (ie homozygous) unrelated donor in an HLA homozygous 
Selection of histocompatible unrelated donors
optional, since the relevance of donor/recipient mismatches HLA loci to be typed: After some debate the following consensus was reached. In the unrelated setting, HLA-A, HLAfor these HLA loci for transplantation outcome is not (yet) stated. B, HLA-DRB1 and HLA-DQB1 typing of the recipient and his/her prospective donor(s) is compulsory. While serological HLA-A, B typing results are (still) accepted as outlined Acceptable HLA mismatches: 11, 12 If at all feasible an HLA-A, B, DRB1-matched unrelated donor should be used. If in Table 2 , HLA DRB1 and DQB1 DNA typing at high resolution is strongly recommended (cf. Table 3 ). Donor this type of donor is unavailable the conference agreed to accept a partially HLA-A, B, DRB1-matched unrelated volselection must be based on the typing results for HLA-A, HLA-B and HLA-DRB1 (six HLA loci). If more than one unteer under the circumstances outlined in Table 4 . The decision not to continue UMDS in order to identify a fully HLA-A, B, DRB1-identical donor is available, donors also matched for HLA-DQB1 with the patient should be pre-HLA-matched volunteer and to proceed to transplant with a partially HLA-matched unrelated donor seems to be justiferred. 9 Recently, HLA-C disparity has been identified as constituting a risk factor for engraftment after BMT from fied if transplantation is highly urgent on clinical grounds (no time left for further UMDS searches) or if the patient's unrelated donors in CML. 10 Thus, in the case of CML we recommend additional DNA-based HLA-C typing if several HLA-A, B, DRB1 phenotype is extremely rare (no realistic chance of finding a fully HLA-matched donor). The final HLA-A, B, DRB1-matched unrelated donors are available. Additional HLA-DPB1 and HLA-DRB3-5 typing is only decision whether to accept or to reject a possible donor has to be made on an individual basis by the transplanting physician. Usually this decision is made in a clinical confer- tories engaged in UMDS (cf. pairs, high resolution HLA-DRB1 and HLA-DQB1 is
strongly recommended in the unrelated setting (cf. Table 4 ).
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Mixed lymphocyte culture (MLC) vs DNA-based HLA class
Bold = Antigens which cannot be typed reliably by serology and should be confirmed by DNA based typing; ( ) = extremely rare in Caucasians.
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